Work

Modulation of neocortical neurotransmissions by antidepressants and neuromodulatory drugs in human and rodent brain tissue and effect of electrical high-frequency stimulation in human neocortex

Year: 2012
Type: dissertation
Abstract: This work includes investigations into presynaptic effects of various antidepressants and neuromodulatory drugs in the neocortex of different species, and studies of the actions of electrical high-frequency stimulation on endogenous GABA release from human neocortical tissue. In the first part, the effect of antidepressants and drugs acting at neurokinin-1 receptors and KATP channels were investigated on the uptake and release of monoamines from neocortex of humans and rodents. Here we presented three topics, all discussed in the light of possible species differences: (i) We first determined and compared the potencies and selectivity of various 5-HT reuptake inhibitors (SRI, citalopram, fluoxetine, and fluvoxamine), NA reuptake inhibitors (NRI, desipramine, atomoxetine, and (S,S)-reboxetine), and dual 5-HT and NA reuptake inhibitors (SNRI, duloxetine and milnacipran) at 5-HT and NA transporters in native human and rat neocortex. In saturation experiments on synaptosomal [3H]-5-HT and [3H]-NA uptake, the dissociation constants did not indicate species differences although a smaller density of both SERT and NAT was observed in human tissue. Competition experiments have shown marked species differences in drug potencies, especially at the SERT. The rank order of selectivity ratios (SERT/NAT) in human neocortex was as follows: citalopram ≥ duloxetine = fluvoxamine ≥ fluoxetine > milnacipran > desipramine = atomoxetine > (S,S)-reboxetine. Significant species differences in these ratios were observed for duloxetine, atomoxetine, and desipramine. This study provides the first compilation of drug potencies at native human neocortical SERT and NAT. The significant species differences (human vs rat) in drug potency suggest that the general use of rodent data is limited to predict clinical efficacy or profile. (ii) Moreover, we compared the modulatory effect of neurokinin-1-receptor antagonists (NK-1-RAs) at 5-HT transporters in native human and rat neocortical synaptosomes. NK-1-RAs are widely studied for its antidepressant effect; however, the underlying mechanisms are largely unknown. We found that the specific human NK-1-RA L-733060, in contrast to the SSRI fluvoxamine did not inhibited 5-HT uptake in human brain synaptosomes and did not modulate fluvoxamine-induced 5-HT uptake inhibition. Furthermore, SP as well as Sar9Met(O2)11SP, the major agonists at the NK-1-R, did not modulate 5-HT uptake in human tissue. Similar results were found in rat neocortical synaptosomes by using the rat-specific NK-1-RA WIN51708. These results show that in humans, as in rodents, inhibition of the 5-HT transporter is probably not the underlying mechanism of the assumed antidepressant activity of NK-1-RA. (iii) Finally, we investigate if prolonged - as opposed to short - 5-HT uptake blockade by antidepressants can lead to changes in the function of ATP- dependent potassium (KATP) channels. Therefore we studied the effects of KATP channel blockers on electrically evoked [3H]-5-HT release after short- and long- term exposure to 5-HT uptake blockers in rat and mouse neocortical slices. The KATP channel blockade by glibenclamide enhanced the electrically evoked [3H]-5- HT release similarly in rat and in mouse neocortex slices. After short-term blockade (45 min) of 5-HT uptake, glibenclamide still increased the release of [3H]- 5-HT in the rat. Glibenclamide, however, failed to enhance [3H]-5-HT release after long-term uptake blockade (210 min). In the mouse, however, both short- and long-term inhibition of 5-HT reuptake by citalopram prevented the facilitatory effect of glibenclamide. The Na+/K+-ATPase inhibitor ouabain abolished the glibenclamide-induced increase in [3H]-5-HT release in both rat and mouse, suggesting that an operative Na+/K+-ATPase is a prerequisite for activation of KATP channels. The terminal 5-HT1B autoreceptor-mediated feedback control was involved in the glibenclamide-induced increase in [3H]-5-HT release only in mouse neocortical tissue. These results suggest that in the rat long-term uptake blockade leads to an impaired activity of the Na+/K+-ATPase, which increases intracellular ATP and consequently closes KATP channels. In the mouse, however, short-term uptake blockade seems to already reduce the activity of Na+/K+-ATPase and thereby the consumption of ATP. Blockade of 5-HT transporters thus may close KATP channels through increased intracellular ATP. The following slight depolarization seems to facilitate 5-HT release. These results may contribute to a better understanding of the mechanisms involved in the clinical time latency of antidepressant efficacy of monoamine uptake blockers. In the second part of this work, it was demonstrated for the first time an effect of electrical high-frequency stimulation (HFS) on GABAergic neurons in human neocortical slices. For this purpose, we first studied the mechanisms by which electrical HFS evokes GABA release and its dependence on GABAA receptors (GABAARs) activation. As a second approach, we investigated the functional role and localization of these GABAARs in human neocortex tissue. In the presence of the Na+ channel opener veratridine which per se was ineffective, human neocortical slices were stimulated electrically at 130 Hz (HFS) in vitro and both basal and stimulation-evoked GABA and glutamate release were measured by HPLC. Our results show that HFS/veratridine in the human brain selectively increased GABA, but not glutamate, release at the site of stimulation. These GABA-specific actions of HFS were abolished by the GABA antagonists, suggesting that HFS has an activating effect on GABAergic neuronal terminals, depending on Na+ and Cl- influx. HFS/veratridine-induced GABA release was also abolished by tetrodotoxin and by the Cl--transport blocker furosemide, suggesting that release of GABA may be mediated by action potentials and requires a plasmalemmal Cl- gradient. The evoked GABA release was also inhibited by GABAB receptor activation. Double-immunolabeling showed that GABAARs are localized on the soma and dendrites of GABAergic neurons. To answer the question whether GABAARs also occur on axon terminals from GABAergic neurons, synaptosomes from the human neocortex were prelabeled with [3H]- GABA and depolarized with K+ (15 mM). In support of a terminal localization of these GABAARs, the K+-evoked [3H]-GABA release from synaptosomes was concentration-dependently increased by the GABAAR agonist muscimol, effects that were antagonized by the GABAAR blockade. Furthermore, the muscimol effect on K+-evoked [3H]-GABA release was also abolished by furosemide, indicating that the terminal facilitatory GABAA autoreceptors become operative through an inverse Cl- gradient. Both K+-evoked [3H]-GABA release from synaptosomes and its enhancement by muscimol were inhibited by Ca2+ withdrawal and by GABA transport inhibition, suggesting two modes of GABAA autoreceptor-facilitated [3H]- GABA release in synaptosomes, one by exocytosis, and the other by transporter reversal. We conclude that HFS in human brain neocortex leads to an increase of GABA (but not of glutamate) release, which is mediated by facilitatory GABAA autoreceptors. These GABAARs utilize an inverse Cl- gradient and are located on soma, dendrites and axon terminals of GABAergic neurons. Taken together, our results may help to better understand the functionality of facilitatory GABAARs and its involvement in the neuronal events during HFS in human brain tissue.
Author: Mantovani, Michela
Language: English
Open Access status: green
OpenAlex ID: W7067827009
Cites: 246
Cited by:
Related to: 10